Distinguished in Non-Small Cell Lung Cancer (NSCLC)

Dr. Caroline Mccoach

Internal Medicine
University Of California San Francisco Medical Center At Mount Zion
1600 Divisadero St, 
San Francisco, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Non-Small Cell Lung Cancer (NSCLC)
University Of California San Francisco Medical Center At Mount Zion
1600 Divisadero St, 
San Francisco, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Caroline Mccoach is a primary care provider, practicing in Internal Medicine in San Francisco, California. Dr. Mccoach is rated as a Distinguished provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, Lung Adenocarcinoma, and Tissue Biopsy.

Her clinical research consists of co-authoring 47 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 27 articles and participated in 6 clinical trials in the study of Non-Small Cell Lung Cancer (NSCLC).

Specialties
Internal Medicine
Licenses
Student in an Organized Health Care Education/Training Program in CO
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

University of California San Francisco Medical Center at Mount Zion
1600 Divisadero St, San Francisco, CA 94143

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Systemic Therapy for Lung Cancer
Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Systemic Therapy for Lung Cancer
Enrollment Status: Recruiting
Publish Date: February 06, 2025
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 21, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 3
Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions
Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions
Enrollment Status: Terminated
Publish Date: June 28, 2023
Intervention Type: Drug
Study Drug: Tarloxotinib bromide
Study Phase: Phase 2
Ph1b/2 Open-Label,Multicenter Dose-Esc & Dose-Exp Study of Combo RMC4630 & Cobimetinib in Participants w/Relapsed/Refractory Solid Tumors & Ph1b Study of RMC4630 w/Osimertinib in Participants w/EGFR Mutation+,Locally Adv or Meta NSCLC
Ph1b/2 Open-Label,Multicenter Dose-Esc & Dose-Exp Study of Combo RMC4630 & Cobimetinib in Participants w/Relapsed/Refractory Solid Tumors & Ph1b Study of RMC4630 w/Osimertinib in Participants w/EGFR Mutation+,Locally Adv or Meta NSCLC
Enrollment Status: Completed
Publish Date: June 26, 2023
Intervention Type: Drug
Study Drugs: RMC-4630, Cobimetinib, Osimertinib
Study Phase: Phase 1/Phase 2
A Phase I Study of Brigatinib With Binimetinib in Advanced ALK- or ROS1-Rearranged Non-Small Cell Lung Cancer (NSCLC)
A Phase I Study of Brigatinib With Binimetinib in Advanced ALK- or ROS1-Rearranged Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: October 17, 2022
Intervention Type: Drug
Study Drugs: Binimetinib, Brigatinib
Study Phase: Phase 1
A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants With Relapsed/Refractory Solid Tumors
A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants With Relapsed/Refractory Solid Tumors
Enrollment Status: Unknown
Publish Date: September 01, 2022
Intervention Type: Drug
Study Drug: RMC-4630
Study Phase: Phase 1
View 5 Less Clinical Trials

47 Total Publications

Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC.
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC.
Journal: JTO clinical and research reports
Published: December 10, 2023
Similar Doctors
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Andrew Ng
Internal Medicine
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Andrew Ng
Internal Medicine

Acn Medical Group Inc.

423 Broadway, 
Millbrae, CA 
 (12.9 miles away)
650-732-9721
Languages Spoken:
English
See accepted insurances

Andrew Ng is a primary care provider, practicing in Internal Medicine in Millbrae, California. Dr. Ng is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Dementia, Stroke, Non-Small Cell Lung Cancer (NSCLC), and EGFR Positive Lung Cancer.

Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Farrell Barnett
Internal Medicine
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Farrell Barnett
Internal Medicine

Eastmont Wellness

6955 Foothill Blvd Ste 200, 
Oakland, CA 
 (15.9 miles away)
510-304-6045
Languages Spoken:
English
See accepted insurances

Farrell Barnett is a primary care provider, practicing in Internal Medicine in Oakland, California. Dr. Barnett is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Small Cell Lung Cancer (SCLC), Squamous Cell Lung Carcinoma, Lung Adenocarcinoma, and Non-Small Cell Lung Cancer (NSCLC).

Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Paul Laband
Internal Medicine
Advanced in Non-Small Cell Lung Cancer (NSCLC)
Dr. Paul Laband
Internal Medicine

Providence Hospice Napa Valley

414 S Jefferson St, 
Napa, CA 
 (35.4 miles away)
707-258-9080
Languages Spoken:
English
See accepted insurances

Paul Laband is a primary care provider, practicing in Internal Medicine in Napa, California. Dr. Laband is rated as an Advanced provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). His top areas of expertise are Coronary Heart Disease, Small Cell Lung Cancer (SCLC), Squamous Cell Lung Carcinoma, and Non-Small Cell Lung Cancer (NSCLC).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mccoach's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile